Peace of Mind for Your Heart -- References
To ensure the highest quality of content, we use only the latest and most complete primary research the medical community has to offer. All content written and researched by RealAge, Inc., has been peer-reviewed by members of the RealAge Scientific Advisory Board.
References
Combined genome-wide scan for prostate cancer susceptibility genes. Gillanders, E. M., Xu, J., Chang, B. L., Lange, E. M., Wiklund, F., Bailey-Wilson, J. E., Baffoe-Bonnie, A., Jones, M., Gildea, D., Riedesel, E., Albertus, J., Isaacs, S. D., Wiley, K. E., Mohai, C. E., Matikainen, M. P., Tammela, T. L., Zheng, S. L., Brown, W. M., Rokman, A., Carpten, J. D., Meyers, D. A., Walsh, P. C., Schleutker, J., Gronberg, H., Cooney, K. A., Isaacs, W. B., Trent, J. M., Journal of the National Cancer Institute 2004 Aug 18;96(16):1240-7.
Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. Catalona, W. J., Richie, J. P., Ahmann, F. R., Hudson, M. A., Scardino, P. T., et al., Journal of Urology 1994 May;151(5):1283-90.
Early detection of prostate cancer. Part II: Estimating the risks, benefits, and costs. Coley, C. M., Barry, M. J., Fleming, C., et al., Annals of Internal Medcine 1997; 126: 468-479.
Effect of ejaculation on serum total and free prostate-specific antigen concentrations. Herschman, J. D., Smith, D. S., Catalona, W. J., Urology 1997 Aug;50(2):239-43.
Ejaculation increases the serum prostate-specific antigen concentration. Tchetgen, M. B., Song, J. T., Strawderman, M., Jacobsen, S. J., Oesterling, J. E., Urology 1996 Apr;47(4):511-6.
New information about prostate-specific antigen and the paradoxes of prostate cancer. Lange PH. :Journal of the American Medical Association. 1995 Jan 25;273(4):336-7.
Pain during prostate biopsy. Luscombe, C. J., Cooke, P. W., Lancet 2004 Jun 5;363(9424):1840-1.
Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. D'Amico, A. V., Chen, M. H., Roehl, K. A., Catalona, W. J., New England Journal of Medicine 2004 Jul 8;351(2):125-35.
Presentation and clinical course of patients ultimately succumbing to carcinoma of the prostate. Thompson, I. M., Zeidman, E. J., Scandinavian Journal of Urology and Nephrology 25 (2): 111-4, 1991.
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford. E. D., Crowley, J. J., Coltman, C. A. Jr., New England Journal of Medicine 2004 May 27;350(22):2239-46.
Prostate Cancer for Screening, Summary Recommendations. U.S. Preventive Services Task Force. 2002. Online at: http://www.ahrq.gov/clinic/uspstf/uspsprca.htm
The Prostate Specific Antigen Era In The United States Is Over For Prostate Cancer: What Happened In The Last 20 Years? Stamey, T. A., Caldwell, M., McNeal, J. E., Nolley, R., Hemenez, M., Downs, J. J., Urology 2004 Oct;172(4, Part 1 Of 2):1297-1301.
Reference ranges for serum prostate-specific antigen in black and white men without cancer. Weinrich, M. C., Jacobsen, S. J., Weinrich, S. P., Moul, J. W., Oesterling, J. E., et al., Urology 1998 Dec;52(6):967-73.
Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force. Harris, R., Lohr, K. N., Annals of Internal Medicine 2002;137:917-29.
Using the magnitude of PSA bounce after MRI-guided prostate brachytherapy to distinguish recurrence, benign precipitating factors, and idiopathic bounce. Das, P., Chen, M. H., Valentine, K., Lopes, L., Cormack, R. A., Renshaw, A. A., et al., International Journal of Radiation Oncology Biology Physics 2002 Nov 1;54(3):698-702.
